In short: Harrington's best-argued single name of the show, and the one she builds a general test out of. Setup: "down 6% on the year with a 13 times multiple and a 10% free cash flow yield and double digit earnings growth ahead. I think DocuSign is totally de-risked" into Thursday's print. The test is a personal experiment: she used ChatGPT to build a calendar that would previously have needed Adobe and real graphic-design skill — "I can do that easily with ChatGPT. What I cannot do with ChatGPT is recreate DocuSign, which we use in the office all day, every day. DocuSign's unique. They have networks in place, security in place, pipelines in place to get things in and out. That is not easily replicable." On the chart: it is up 24% in three months, but she attributes that to the systemic semis→software rotation since the end of June rather than to the company. Verdict: "10% free cash flow yield at 13 times. Thank you, buy it now."
DocuSign is the electronic-signature service. Jenny Harrington's argument is the most useful thing on the show because it is a test anyone can run, not a stock tip.
She spent a weekend on a personal project — making a calendar — that previously would have required Adobe's software and real design skill, and did it easily with ChatGPT instead. Then she asked the mirror-image question: could ChatGPT recreate DocuSign, which her office uses every single day? No. Signing documents legally is not a design task; it depends on connections to other companies' systems, on security and audit trails, and on the plumbing that gets documents in and back out again. That is expensive to rebuild and impossible to fake, which is why she thinks the AI-disruption discount being applied to all software is wrong here.
The price does the rest of the work. The stock is down 6% on the year at about 13 times earnings, and for every $100 of market value the business throws off roughly $10 of spare cash a year — a 10% free-cash-flow yield — with double-digit profit growth expected. Her verdict into Thursday's results: "totally de-risked… buy it now."
In short: Second of the newsletter's three round-trip examples — ran hard from 2019 into 2021 "and then also gave all that back practically." Cited as the shape of what a crowded momentum name does, not as a rating.
8:00You pointed out how Zoom rose 700% between December 2019 and October 2020 and then surrendered that entire gain by December of 2022. DocuSign went from $44 in 2019 to $36 in 2021 and then also gave all that back practically. Peloton that was a big one rising from $24 to 158 before collapsing.
In short: Q1 rev +9% to $830M, EPS $1.09 (up from $0.86), a record $318M buyback. The story is IAM (Intelligent Agreement Management) — 12.6% of ARR (up from 10.8%), tracking to 18% by year-end (~$600M+ ARR) — on a structural shift from per-signature to credit-based, outcome-tied pricing. New Anthropic/OpenAI/Harvey/Thomson Reuters integrations. A disclosed author holding.
DocuSign is best known for electronic signatures, but its growth bet is "IAM" (Intelligent Agreement Management) — software that doesn't just sign a contract but helps create, review, track, and act on agreements, increasingly with AI agents. IAM is now 12.6% of recurring revenue (up from 10.8%) and management expects 18% by year-end, so the newer, stickier product is scaling.
The interesting shift is how it charges: instead of billing per signature, the new plan uses "credits" tied to outcomes — customers buy a pool of usage and spend it across tasks. That can grow revenue per customer as they use more AI features. DocuSign also reported a record share buyback (returning cash to owners) and is wiring in outside AI models (Anthropic's Claude, OpenAI) and partners (Harvey, Thomson Reuters). The pitch, backed by a Deloitte study it cited, is that end-to-end platforms deliver far more AI return than scattered point tools.
In short: "At significant risk" — its core e-signature product faces "massive bundling risk" from Adobe, Microsoft and startups; "what they do is not technically difficult anymore."
DocuSign's main product is electronic signatures. Carlson puts it in the "at significant risk" bucket of his software split because e-signing is no longer technically hard — Adobe, Microsoft and many startups can offer it and simply bundle it into bigger products customers already pay for.
When a feature can be copied and given away inside someone else's suite, the standalone version tends to get a permanently lower valuation. That "massive bundling risk" is why he avoids it, even though the stock has already fallen a lot.
19:09They might do well, but I'm really not confident in any direction. I think that DocuSign is at significant risk. This company's major product is simply e-signatures and I believe that there's massive bundling risk. Like Adobe's coming after DocuSign, we have Microsoft, all these different startups that are offering signature-based documents.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.